Encompass Health Corporation filings document the operating results, financing arrangements and governance matters of a public inpatient rehabilitation hospital company. Its Form 8-K reports furnish earnings releases, Regulation FD materials, same-store performance measures and non-GAAP metrics such as adjusted earnings per share, leverage ratio, Adjusted EBITDA and adjusted free cash flow.
Other filings record capital-structure and governance subjects, including the company's credit agreement, revolving credit facility, subsidiary guarantor arrangements, board appointments, committee assignments and director compensation practices. The definitive proxy statement addresses annual meeting proposals, executive compensation, pay-versus-performance disclosure, board structure and stockholder voting matters.
Encompass Health Corp. President & CEO Mark J. Tarr, who is also a director, reported multiple open-market sales of company common stock on February 11, 2026.
He sold a total of 150,000 shares at weighted-average prices ranging from $107.47 to $113.58 per share, and directly owned 377,070 shares of Encompass Health common stock after these transactions.
Invesco Ltd. has reported a significant shareholding in Encompass Health Corp. As of 12/31/2025, Invesco, as a parent holding company to its investment advisers, may be deemed to beneficially own 4,972,725 shares of Encompass Health common stock, representing 4.9% of the class.
Invesco has sole voting power over 4,761,846 shares and sole dispositive power over 4,972,725 shares, with no shared voting or dispositive power. The shares are held of record by clients of Invesco’s advisers, and no single individual has more than 5% economic ownership.
Invesco certifies that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Encompass Health, consistent with a passive investment reported on a Schedule 13G/A.
Encompass Health Corporation has a planned sale of restricted or control securities under Rule 144. The notice covers up to 150000 shares of common stock, with an aggregate market value of 16738961, to be sold through UBS Financial Services Inc. on the NYSE.
The filing states that 100615977 shares of the issuer’s common stock are outstanding. It also shows an acquisition entry where common stock was acquired on 02/17/2020 via RSA vesting from Encompass Health Corporation, with 2514 securities in that transaction.
Encompass Health Corp. executive vice president and chief operating officer Patrick William Tuer sold 2,804 shares of Encompass Health common stock in an open market transaction on February 10, 2026. The shares were sold at a weighted average price of $107.62 per share, in multiple trades ranging from $107.55 to $107.73. Following this sale, Tuer directly beneficially owns 16,042 shares of Encompass Health common stock.
Encompass Health Corporation has a shareholder filing a notice to sell 2,804 shares of its common stock under Rule 144. The planned sale through UBS Financial Services Inc. is listed with an aggregate market value of 301755, with trading on the NYSE around 02/10/2026.
The shares to be sold were acquired from Encompass Health Corporation through restricted stock unit vesting on 02/23/2024 and 02/24/2024, and performance stock unit vesting on 01/01/2025. Shares outstanding were 100,615,977 common shares at the time referenced.
Encompass Health Corporation filed a Form 8‑K to furnish its financial results for the three months and year ended December 31, 2025, as disclosed in a press release (Exhibit 99.1) and supplemental earnings materials (Exhibit 99.2).
The company explains its use of same‑store comparisons, which include hospitals open in both periods and incorporate market consolidations and capacity expansions where isolating incremental impact is difficult. It also highlights several non‑GAAP measures: adjusted earnings per share, Adjusted EBITDA, leverage ratio, and adjusted free cash flow.
Encompass Health describes how Adjusted EBITDA and its leverage ratio are central to covenants in its credit agreement, affecting the ability to incur debt, pay dividends, and make certain investments. The filing also outlines the company’s definition of adjusted free cash flow and includes extensive cautionary language about forward‑looking statements tied to its strategy, growth targets, capital plans, and financial outlook.
Encompass Health Corporation reported that its Board of Directors elected Cain A. Hayes as a director on January 30, 2026, following a recommendation from its Nominating/Corporate Governance Committee. The Board has determined that Mr. Hayes is independent under New York Stock Exchange listing standards and the company’s Corporate Governance Guidelines.
Mr. Hayes will receive compensation consistent with the company’s standard practices for nonemployee directors, as described in its April 1, 2025 proxy statement. The company stated there are no arrangements or understandings with other persons related to his selection and no related party transactions involving him that require disclosure. A press release dated February 2, 2026, announcing his election, is included as an exhibit.
Encompass Health Corp reported an equity award to director Cain A. Hayes. On January 30, 2026, Hayes received 457 shares of Encompass Health common stock at a price of $0 per share, granted as restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan. Following this award, Hayes directly beneficially owns 457 shares of Encompass Health common stock.
Encompass Health Corp filed an initial ownership report for director Cain A. Hayes. The filing states that, as of the event date of 01/30/2026, he is a director of the company and that no Encompass Health securities are beneficially owned.
Encompass Health Corp director Greg D. Carmichael reported receiving 28 shares of Encompass Health common stock on January 15, 2026, recorded at a price of $0 per share as a stock-based award. Following this transaction, he beneficially owned 18,659 shares directly.
The filing explains that this award reflects additional restricted stock units credited to non-employee directors in connection with common stock dividend payments. On January 15, 2026, Encompass Health paid a $0.19 per share dividend when the stock’s closing price was $102.80, and the 28 RSUs reported are tied to that dividend-related accrual.